Reviva Pharmaceuticals announced that it will host a key opinion leader, KOL, event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP and Mark Opler, PhD, MPH, who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine, a next-generation serotonin/dopamine modulator, as a potential treatment. To register, click here.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVPH:
- Reviva Pharmaceuticals files $200M mixed securities shelf
- Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
- Reviva Pharmaceuticals provides program updates, upcoming milestones
- Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
- Reviva may be most undervalued in neurology, says H.C. Wainwright
